Management of chronic hepatitis C

Minerva Gastroenterologica e Dietologica

Volumn 53, Issue 1, 2007, Pages 9-23

  Asselah, T ^a   Boyer, N ^a   Ripault, M P ^a   Martinot, M ^a   Marcellin, P ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BEAUJON HOSPITAL   (France)

Author keywords

Hepatitis C, drug therapy; Hepatitis C, natural history; Interferons; Treatment outcome

Indexed keywords

ALBUMIN ALPHA INTERFERON; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PROTEINASE INHIBITOR; RIBAVIRIN; UNCLASSIFIED DRUG; VALOPICITABINE; VX 950;

ANEMIA; ARTHRALGIA; ASTHENIA; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DRUG HALF LIFE; DRUG MECHANISM; DRY SKIN; EUROPE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HAIR LOSS; HEADACHE; HEART DISEASE; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; IRRITABILITY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MENTAL DISEASE; MOOD CHANGE; PHENOTYPE; REVIEW; RISK FACTOR; SEX DIFFERENTIATION; SHIVERING; SIDE EFFECT; SLEEP DISORDER; UNITED STATES; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; DECISION TREES; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; RIBAVIRIN;

EID: 34250897936     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. EASL International Consensus Conference on Hepatitis C. Consensus Statement. J Hepatol 1999;30:956-61.
2. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C. Hepatology 2002;36 Suppl 1:S3-20.
3. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36:S47-56.
4. Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, Smoak B et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-11.
5. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL et al. Long-term mortality after transfusion associated non-A non-B hepatitis. N Engl J Med 1992;327:1906-11.
6. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;340:1228-33.
7. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-years multicenter study. Hepatology 2000;32:91-6.
8. Poynard T, Ratziu V, Charlotte F, Goodman Z, Mchutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-9.
9. Codes L, Asselah T, Cazals-Hatem D, Tubach F, Vidaud D, Parana R et al. Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of menopause and steatosis and the potential benefit of hormone replacement therapy. Gut 2007;56:390-5.
10. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998;27:1717-22.
11. Soriano V, Garcia-Samaniego J, Bravo R, Gonzalez J, Castro A, Castilla J et al. Interferon a for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:585-91.
12. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M et al. Influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001;34:1193-9.
13. Peffault de Latour R, Levy V, Asselah T, Marcellin P, Scieux C, Ades L et al. Long-term outcome of hepatitis C infection after bone marrow transplantation. Blood 2004;103:1618-24.
14. Asselah T, Martinot M, Boyer N, Marcellin P. Variabilité génétique du virus de l'hépatite C: implications cliniques. Gastroenterol Clin Biol 2000;24:175-84.
15. Martinot-Peignoux M, Marcellin P, Gournay J, Gabriel F, Courtois F, Branger M et al. Detection and quantitation of serum hepatitis C virus (HCV) RNA by branched DNA amplification in anti-HCV positive blood donors. J Hepatol 1994;20:676-8.
16. Marcellin P, Akrémi R, Cazals D, Boyer N, Aupérin A, Vidaud D et al. Genotype 1 is associated with a slower progression of fibrosis in untreated patients with mild chronic hepatitis C. J Hepatol 2001;34:159A.
17. Asselah T, Martinot M, Cazals-Hatem D, Boyer N, Aupérin A, Le Breton V et al. Hypervariable region 1 quasispecies in hepatitis C virus gentotype 1b and 3 infected patients with normal and abnormal serum alanine aminotransferase levels. J Viral Hepatitis 2002;9:29-35.
18. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
19. Asselah T, Boyer N, Guimont MC, Cazals-Hatem D, Tubach F, Nahon K et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 2003;52:1638-43.
20. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-9.
21. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis G why does it really matter? Gut 2006;55:122-30.
22. Thomas HC, Törok ME, Forton DM, Taylor-Robinson SD. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol 1999;32:152-9.
23. Boyer N, Marcellin P. [Pegylated interferon: new progress in treatment for chronic hepatitis C] Gastroenterol Clin Biol 2000;24:767-9. French.
24. Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998;79:2381-91.
25. Agence Nationale d'Accreditation et d'Evaluation en Sante (ANAES). Consensus conference. Treatment of hepatitis C. Gastroenterol Clin Biol 2002;26 Spec No 2:B303-20. English, French.
26. Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000;32:98-112.
27. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
28. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
29. Asselah T, Boyer N, Marcellin P. Traitement de l'hépatitie C. Encycl Med Chir. Hépatologie 2003,7-015-B-51.
30. Poynard T, Marcellin P, Lee SS, Niederau C, Minuck GS, Ideo G et al. Randomised trial of interferon a2b plus ribavirin for 42 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of crhonic infection with hepatitis C virus. Lancet 1998;339:1458-92.
31. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. Interferon alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1458-92.
32. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666-72.
33. Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-80.
34. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403.
35. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
36. Rockey DC, Chung JJ. Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis. J Invest Med 1994;42:660-70.
37. Mallat A, Preaux AM, Blazejewski S, Rosenbaum J, Dhumeaux D, Mavier P. Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture. Hepatology 1995;21:1003-10.
38. Manabe N, Chevallier M, Chossegros P, Causse X, Guerret S, Trepo C et al. Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology 1993;18:1344-9.
39. Duchatelle V, Marcellin P, Giostra E, Bregeaud L, Pouteau M, Boyer N et al. Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method. J Hepatol 1998;29:20-8.
40. Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997;127:875-81.
41. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-24.
42. Shiffman ML, Hofmann CM, Contos MJ, Luketic VA, Sanyal AJ, Sterling RK et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 1999;117:1164-72.
43. Sobesky R, Mathurin P, Charlotte F, Moussalli J, Olivi M, Vidaud M et al. Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group. Gastroenterology 1999;116:378-86.
44. Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet 2001;357:196-7.
45. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-7.
46. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997;25:754-8.
47. Fattovich G, Giustina G, Degos F, Diodati G, Tremolada F, Nevens F et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997;27:201-5.
48. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998;351:1535-9.
49. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-40.
50. Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer 1998;83:901-9.
51. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999;29:1870-5.
52. Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000;47:131-6.
53. Gramenzi A, Andreone P, Fiorino S, Camma C, Giunta M, Magalotti D et al. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001;48:843-8.
54. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnu L, Mazzella G et al.; Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-87.
55. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995;22:1050-6.
56. Couzigou P. Quality of life of patients with chronic hepatitis C: effect of treatments. Gastroenterol Clin Biol 2002;26:B257-63.
57. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol 1995;22:364-9.
58. Schalm SW, Weiland O, Hansen BE, Milella M, Lai MY, Holaander A et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Gastroenterology 1999;117:408-13.
59. Marrache F, Consigny Y, Ripault MP, Cazals-Hatem D, Martinot M, Boyer N et al. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. J Viral Hepat 2005;12:421-8.
60. Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23.
61. Moucari R, Ripault MP, Oulès V, Martinot M, Asselah T, Boyer N et al. High predictive value of early viral kinetics in retreatment with peginterferon and ribavirine of chronic hepatitis C patients non responders to standard combination therapy. J Hepatol 2007;46:596-604.
62. st EASL, 2006, April 26-29, Vienna, Austria.
63. Kamal SM, El Tawil AA, Nakano T, He Q, Rasenack J, Hakam SA et al. Peginterferon (alpha)-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005;54:858-66.
64. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M et al. Peginterferon alfa-2b and ribavirin for 12 vs 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
65. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7.
66. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
67. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97.
68. Yao N, Hesson T, Cable M, Hong Z, Kwong AD, Le HV et al. Structure of the hepatitis C virus RNA helicase domain. Nat Struct Biol 1997;4:463-7.
69. Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA et al. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996;87:343-55.
70. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003;426:186-9.
71. Hinrichsen H, Benhamou Y, Wedemeyer H, Reiser M, Sentjens RE, Calleja JL et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 2004;127:1347-55.
72. Asselah T, Marcellin P. BILN 2061: a major step toward new therapeutic strategies in hepatitis C. J Hepatol 2004;41:178-81.
73. Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon ?-2b for genotype 1 nonresponders. Gastroenterology. In press.
74. Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002.
75. Reesink HW, Forestier N, Weegink CJ, Zeuzem S, McNair L, Purdy S et al. Interim results of a 14 day study of the hepatitis C protease inhibitor VX-950, in combination with pegylated interferon alfa 2a. EASL, 2006, April 26-30, Vienna, Austria.
76. Lawitz E, Nguyen T, Younes Z, Santoro J, Gitlin N, McEniry D et al. Valopicitabine (NM283) plus PEG interferon in treatment naïve hepatitis C patients with HCV genotype 1: HCV RNA clearance during 24 weeks of treatment. Hepatology 2006;44:A223.
77. Nelson D, Rustgi V, Balan V, Sulkowski M, McHutchison J, Davis GL et al. Sustained virologic response rates with albumin interferon alfa-2b in combination with ribavirin in non-responders to prior interferon therapy: interim results from a Phase 2 study. 57th Annual Meeting of the American Association for the Study of Liver Diseases, 2006, October 27-31, Boston, MA.
78. Bain VG, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006;44:671-8.
79. Moradpour D, Blum HE. A primer on the molecular virology of hepatitis C. Liver Int 2004;24:519-25.
80. Abrignani S, Houghton M, Hsu HH. Perspectives for a vaccine against hepatitis C virus. J Hepatol 1999;31:259-63.
81. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-6.
82. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-6.
83. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005;102:9294-9.